News about Global Pharma

Titan Pharmaceuticals Completes Merger with Black Titan and TalenTec

Titan Pharmaceuticals has completed its merger with Black Titan Corporation, a Cayman Islands exempted company, and TalenTec, a Malaysian private limited company. The transaction closed successfully on October 1, 2025, making Titan a wholly owned subsidiary of Black Titan.

Global Pharma | 04/10/2025 | By Dineshwori |  660

Daiichi Sankyo Establishes Third Research Institute in San Diego

Daiichi Sankyo Research Institutes, located in Boston, Munich and San Diego, are advancing the vision of Daiichi Sankyo to foster the development of next-generation medicines.

Global Pharma | 04/10/2025 | By Dineshwori |  142

India's USD 12 Billion MedTech Sector Set to Surge to USD 50 billion by 2030: Dr Jitendra Singh

Union Minister Dr. Jitendra Singh noted that institutions like SCTIMST, with recognition from WHO and collaborations with national agencies such as ICMR, DBT, CSIR, DRDO and INSA, can contribute to India’s emergence as a global hub for cost-effective healthcare and medical tourism by 2047.

Global Pharma | 04/10/2025 | By Dineshwori |  189

Celltrion Launches Tocilizumab Biosimilar AVTOZMA IV in the US Market

AVTOZMA is Celltrion's fifth immunology biologic and seventh biosimilar approved by the US FDA. It will be available in the same presentations as its reference product, Actemra (tocilizumab).

Global Pharma | 03/10/2025 | By Dineshwori |  426

Lupin Launches Generic Xarelto Rivaroxaban Oral Suspension in US

Global pharma major Lupin has announced the launch of Rivaroxaban for Oral Suspension, 1 mg/mL, in the United States.

Global Pharma | 03/10/2025 | By Dineshwori |  377

Amcor to Showcase Sustainable and Patient-Centric Packaging Innovations at CPHI Frankfurt 2025

At CPHI Frankfurt 2025, Amcor will highlight its extensive portfolio of rigid and flexible packaging solutions, including ClariPPil jars and OSD bottles for oral solid dose applications, alongside its AmSky and high-shield pharma laminates.

Global Pharma | 03/10/2025 | By Dineshwori |  453

FDA Approves Novartis's Rhapsido as First Oral BTK Inhibitor for Chronic Spontaneous Urticaria

The US Food and Drug Administration (FDA) has approved Novartis’ Rhapsido (remibrutinib) as an oral treatment for adult patients with chronic spontaneous urticaria (CSU) who continue to experience symptoms despite H1 antihistamine therapy.

Global Pharma | 03/10/2025 | By Dineshwori |  394

Novavax, Sanofi Deepen Partnership to Include Matrix-M in Pandemic Influenza Vaccine Programme

The expanded partnership allows Sanofi to use Novavax’s Matrix-M adjuvant in its pandemic influenza vaccine candidate programme.

Global Pharma | 01/10/2025 | By Dineshwori |  287

Artemis Acquires Millrock Technology

Under Artemis' ownership, Millrock will continue to operate as an independent company from its facility in Kingston, New York, serving a global customer base.

Global Pharma | 01/10/2025 | By Dineshwori |  246

AbbVie Expands US Biologics and API Manufacturing Capacity, Seeks FDA Approval for Rare Blood Cancer Therapy

AbbVie has begun a USD 70 million expansion of its AbbVie Bioresearch Center (ABC) in Worcester, Massachusetts, and broken ground on a new North Chicago Active Pharmaceutical Ingredient (API) manufacturing facility.

Global Pharma | 01/10/2025 | By Dineshwori |  269